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Chemical antagonists were used to assess the role of @-endorphin and arginine-vasopressin (AVP) in 
canine endotoxin shock. Fifteen awake dogs were given Escherichia coli endotoxin IV. Within 5 min, 
CO decreased to 282, LV dP/dt to 46%, and MAP to 52% of baseline. Fifteen minutes after endotoxin, 
five do8s each received naloxone, AVP antagonist, or no treatment. Control (untreated) animals exhibited 
persistent cardiovascular depression, with CO 49%, LV dP/dt 691, and MAP 9 1% of baseline after 45 
min. Naloxone improved CO to 69%, LV dP/dt to 94%, and MAP to 91% by 30 min after treatment. 
AVP blockade improved CO to 105%, LV dP/dt to 107%, and h4AP to 95% of baseline by 30 min after 
treatment, and caused significant tachycardia. Plasma cortisol and AVP increased markedly in all 
groups after endotoxin administration. AVP antagonist treatment increased mean survival from 1.4 to 
4 days. These data suggest that abnormally elevated AVP contributes to cardiovascular depression 
in canine endotoxin shock and that AVP blockade is therapeutic in the animal model studied. o 1986 
INTRODUCTION 
Endotoxin administration in dogs causes 
profound cardiovascular collapse, character- 
ized by systemic hypotension and low cardiac 
output [ 171. Although the mechanism of this 
response is not completely understood, a va- 
riety of factors including hepatic venocon- 
striction, reduced systemic venous return, cir- 
culating myocardial depressant factor, and di- 
rect myocardial effects, have been implicated 
[16, 18, 19, 25, 341. Opiate antagonism with 
naloxone has been found to increase survival 
and improve cardiac performance in rats and 
dogs during endotoxin shock [7,35,36]. Since 
opiates exert a centrally mediated myocardial 
depressant effect [24], these studies suggested 
that endogenous opiates (endorphins), known 
to be elevated in septic shock [5], might con- 
tribute to hemodynamic deterioration. 
Plasma levels of arginine-vasopressin 
(AVP) also increase markedly in dogs during 
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endotoxin or hemorrhagic shock, much more 
than occurs during water deprivation [28,44]. 
Furthermore, AVP has been shown to cause 
myocardial depression in dogs, both in vivo 
and in an isolated left ventricle preparation 
[29, 431. These observations suggested the 
possibility that excessively high AVP activity 
in endotoxin shock might contribute substan- 
tially to cardiac depression. Our study was de- 
signed to test this hypothesis by treating en- 
dotoxin shocked dogs with a specific AVP an- 
tagonist and comparing the observed hemo- 
dynamic changes and survival with untreated 
control animals. Because of potential inter- 
actions between AVP and P-endorphin, a third 
group of naloxone-treated dogs was studied 
to allow a comparison with AVP antagonist 
effects. 
METHODS 
Fifteen mongrel dogs of both sexes (19-33 
kg), free of dirofilaria and endoparasites, were 
briefly anesthetized (thiamylal sodium) for 
catheter placement 1 day prior to the actual 
experiment. Using sterile surgical technique, 
a cervical incision was used to insert a trans- 
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jugular Swan-Ganz thermodilution catheter 
in the pulmonary artery. A carotid artery 
catheter and a transcarotid left ventricular 
pigtail catheter were inserted through the same 
incision. After the catheters were secured in 
place, the animals were allowed to recover 
from anesthesia and given free access to food 
and water. The animal research protocol fol- 
lowed in this study was approved by the Sub- 
committee for Animal Research, Ann Arbor 
Veterans Administration Medical Center. 
One day after catheter placement, fully 
awake and normal-appearing animals were 
placed in a modified Pavlov stand. Mean sys- 
temic arterial pressure (MAP) and left ven- 
tricular (LV) pressure were continuously re- 
corded. Heart rate was measured with an am- 
plifier triggered by the LV pressure pulse. The 
maximum value during the cardiac cycle of 
the first derivative of LV pressure (dP/dt max, 
hereafter, dP/dt) was electronically derived 
from the LV pressure signal. Cardiac output 
(CO) and temperature were intermittently re- 
corded using the thermodilution Swan-Ganz 
catheter. Hemodynamic variables were ana- 
lyzed and reported at 15-min intervals during 
the 3-hr observation period, in addition to 
measurements made 5 min after endotoxin 
administration and 5 min after drug treatment. 
Stroke volume (SV) was calculated as SV 
= CO/HR (ml/beat). Total peripheral resis- 
tance (TPR) was estimated as TPR = MAP/ 
CO [(mm Hg/liter/min) X 80 = dyne * sec. 
cme5], under the assumption that venous 
pressure contributed negligibly to the result. 
Blood samples obtained through the carotid 
artery catheter were replaced with an equal 
volume of normal saline. 
After the awake dogs had stabilized for 30 
min, baseline hemodynamic measurements 
and blood samples were obtained. Animals 
were then given Escherichia coli endotoxin 
intravenously (0.75 mg/kg IV, Sigma No. L- 
3 124, serotype 0 127:BB, phenol extracted), an 
LDrm dose at 48 hr in pilot studies. Fifteen 
minutes after endotoxin administration, 
treatment was initiated: five control dogs re- 
ceived only normal saline, 2 ml/kg, iv; five 
animals received naloxone, 2 mg/kg iv + 2 
mg/kg/hr iv for 3 hr; five additional dogs re- 
ceived the A VP antagonist I-(B(mercapto+, 
/3-cyclopentamethylenepropionic acid), 2- 
(O-methyl) tyrosine arginine-vasopressin 
(Bachem, Inc.), 10 pg/kg iv [22]. These doses 
were selected because of demonstrated efficacy 
in previous studies [36, 371. Both naloxone 
and AVP antagonist were dissolved and ad- 
ministered in saline, 2 ml/kg. All animals were 
monitored for 180 min after endotoxin ad- 
ministration and received normal saline, 1 ml/ 
kg/hr, during this period. After this observa- 
tion period, the dogs were returned to their 
cages and allowed free access to food and wa- 
ter, but were not treated with antibiotics or iv 
fluids. Catheters were removed under brief 
thiamylal sodium anesthesia on the day fol- 
lowing the experiment. Survival was recorded 
for 7 days, at which time any surviving animal 
was sacrificed. 
Blood samples at baseline, 30 and 90 min 
after endotoxin administration were obtained. 
White blood cell (WBC) count with differen- 
tial, platelet count, and hematocrit were de- 
termined. Ionized calcium was measured from 
heparinized blood immediately after sampling 
(Orion SS-20 Ionized Calcium Analyzer). To- 
tal hemolytic complement was assessed by the 
percentage lysis of sensitized sheep red blood 
cells (RBC) by dog serum. Lysis of 60 X lo6 
RBC by a 1:40 dilution of dog serum after 1 
hr incubation at 37°C was compared to stan- 
dard (100%) lysis by distilled water using op- 
tical density at 540 nm. Plasma epinephrine, 
norepinephrine and cortisol were measured by 
radioimmunoassay [23,32]. Plasma AVP was 
measured by radioimmunoassay from samples 
extracted using Sep pak C, s cartridges (Waters 
Associates). Separation of free from bound 
AVP was achieved by adding rabbit -y-globulin 
and polyethylene glycol [33]. Vasopressin an- 
tagonist was tested for cross reactivity in the 
AVP radioimmunoassay system. The antag- 
onist showed a 0.46% cross reactivity with 
AVP standard. 
Hematologic variables were compared 
within treated groups at baseline, 30 and 90 
min by paired Student’s t test, and between 
treatment groups by non-paired Student’s t 
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TABLE 1 
















(dyne. sec. cme5) 
Temperature 
(“C) 
4.2 -t 0.4 3.8 + 0.8 2.1 k 0.3 2.5 0.13 
112+3 117+7 113k6 0.2 0.80 
llO-+ 11 90*9 111+14 1.0 0.41 
3.1 kO.3 2.8 + 0.3 3.1 kO.3 0.2 0.79 
4os4 44k9 26+4 2.1 0.16 
2240 + 240 2800 + 480 352Ok400 2.6 0.11 
39.4 + 0.1 40.0 + 0.2 39.4 k 0.2 2.9 0.10 
Note. X f  SEA4 F, P values between groups by analysis of variance. Abbreviations: MAP, mean arterial pressure; 
LV dp/dt, left ventricular pressure-time derivative; TPR, total peripheral resistance. 
test. Hemodynamic parameters were com- 
pared between treatment groups and across 
time by multiple analysis of variance. These 
data were then expressed as the ratio to initial 
baseline measurement, to eliminate large in- 
teranimal variations. 
RESULTS 
Baseline hemodynamic parameters showed 
no statistically significant variance between 
treatment groups prior to endotoxin admin- 
istration (Table 1). Apparent differences were 
due to large baseline variation among all dogs 
rather than systematic differences between 
drug treatment groups that were randomly as- 
signed. Immediately after endotoxin admin- 
istration at T (time) = 0, CO fell to 28% of its 
initial level (Fig. 1). After this initial decrease, 
there was a gradual improvement in control 
animals, so that CO achieved 60% of its base- 
line level by 90 min and remained at this level 
during the subsequent 90 min observation pe- 
riod. Naloxone-treated animals demonstrated 
a more rapid improvement in CO than control 
animals, with a return of CO to 80% of baseline 
within 5 min of treatment (T = 20 min). The 
difference between naloxone-treated and con- 
trol animals (P = 0.08) gradually diminished, 
so that CO in both groups was 6570% of 
baseline by T = 180 min. Animals treated with 
AVP antagonist showed a rapid normalization 
of CO, within 10 min of treatment. CO re- 
TREATMENT 
D CONTROL 
. NALOXONE ----- 
. WP ANTAGONIST 
PIG. I. CO fell markedly after endotoxin (E), but re- 
turned to normal atIer drug treatment (T) with AVP an- 
tagonist, significantly better than control (P < 0.01) or 
naloxone (P -z 0.03) groups. 
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mained greater than baseline throughout the 
experiment, being significantly greater than 
control (P < 0.0 1) or naloxone-treated (P 
< 0.03) dogs. 
LV dP/dt decreased to 46% of baseline im- 
mediately after endotoxin administration (Fig. 
2). After treatment with naloxone and AVP 
antagonist, LV dP/dt returned to baseline level 
within 5- 10 min. These drug treatment groups 
were statistically comparable, but were both 
different from control dogs, where LV dP/dt 
returned gradually toward normal only after 
120 min (naloxone > control, P < 0.01; AVP 
antagonist > control, P < 0.05). 
All dogs experienced tachycardia, beginning 
approximately 20 min after endotoxin ad- 
ministration (Fig. 3). AVP antagonist treat- 
ment was associated with the most rapid and 
profound tachycardia, beginning immediately 
after treatment and reaching a level 1.8 times 
baseline after 60 min. Tachycardia in AVP 
antagonist treated dogs was significantly 
greater than control or naloxone-treated 
groups (P < 0.05). Although naloxone-treated 
dogs appeared to develop a more rapid heart 
rate than control animals, this was not statis- 
tically significant. After an initial marked de- 
crease, SV remained significantly depressed in 
all dogs throughout the 180 min observation 
period (Fig. 4). This related primarily to 
TREATMENT 
q CONTROL ______.-.--.__. 
i . NALOXONE ----- 
. A”P ANTAGONIST 
FIG. 2. LV dP/dt decreased 50% after endotoxin (E). 
Compared to control dogs, LV dP/dt returned rapidly to 
normal after drug treatment (T) with naloxone (P < 0.05) 
or AVP antagonist (P -c 0.01). 
TREATMENT 
q CONTROL .._._____._.__- 
. NALOXONE ----- 
‘3 . AVP ANTAGONIST 
O.B! , , , , , , , , , , 
Tk 90 105 120 135 IS0 165 110 
(Minutes) 
FIG. 3. Tachycardia developed after endotoxin (E) in 
all treatment (T) groups. AVP antagonist treated dogs de- 
veloped significantly higher HR than control or naloxone 
dogs (both P < 0.05). 
tachycardia that developed in all groups. Nal- 
oxone and AVP antagonist groups appeared 
to have a higher SV than control animals, 
especially for the first 90 min after treatment, 
but this was not statistically significant. 
After decreasing to 52% of baseline level 
immediately after endotoxin administration, 
MAP remained significantly depressed in 
control animals for the next 90 min, increasing 
gradually toward normal thereafter (Fig. 5). 
Treatment with naloxone or AVP antagonist 
TREATMENT 
. AVP ANTAGONIST 
’ 90 105 00 135 150 165 1.30 
Time (Minutes) 
FIG. 4. After endotoxin (E), SV fell markedly and re- 
mained depressed. Drug treatment (T) with naloxone and 
AVP antagonist appeared to initially improve SV, although 
this was not statistically significant. 
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TREATMENT 
m  CONTROL __- .____.______ 
. NALOXONE ----- 
. AVP ANTAGONIST 
FIG. 5. MAP decreased rapidly after endotoxin (E), re- 
turning nearly to baseline level much more rapidly after 
naloxone (P <: 0.03) or AVP antagonist (P < 0.01) treat- 
ment (T) than in control, untreated dogs. 
rapidly increased MAP to 90- 100% of baseline 
value. This improvement was statistically dif- 
ferent from control animals, where MAP re- 
turned to 90% of baseline only after 150 min 
(naloxone > control, P < 0.03; AVP antago- 
nist > control, P < 0.01). After endotoxin ad- 
ministration, TPR transiently increased, dur- 
ing the early, transient cardiovascular collapse 
(Fig. 6). TPR then decreased toward baseline, 




q CONTROL _-.._____-----_ 
. NALOXONE ----- 
. AVP ANTAGONIST 
FIG. 6. TPR increased transiently after endotoxin (E), 
and remained significantly higher in control (I’ < 0.04) 
and naloxone (P < 0.02) dogs, than in dogs treated (T) 
with AVP antagonist, where TPR was lower than baseline 
after the initial transient increase. 
baseline in both naloxone and control animals 
throughout the experiment. Dogs treated with 
AVP antagonist maintained their TPR below 
baseline, significantly different than control (P 
< 0.04) or naloxone (P < 0.02) groups. Tem- 
perature increased progressively throughout 
the 180 min observation period after endo- 
toxin administration, being statistically com- 
parable in all groups (Fig. 7). 
Hematologic variables showed minor, but 
occasionally statistically significant differences 
between the three treatment groups at baseline 
(Table 2). Since treatment groups were ran- 
domly assigned, these differences appeared to 
result from large variations among individual 
dogs that were not eliminated by the small 
number of animals in each group. In all cases, 
these differences were small compared to the 
subsequent changes observed after experi- 
mental manipulation. After endotoxin ad- 
ministration, WBC count decreased markedly 
(by 30 min) and remained depressed at the 90 
min sample time. This decrease was compa- 
rable in the three treatment groups, with leu- 
kocyte counts decreasing to 15% of their base- 
line value. Differential counting revealed that 
the leukopenia was due to a reduction in het- 
erophilic leukocytes (polymorphonuclear 
forms), which decreased from 85% of the total 
leukocyte count at baseline to 38% of the leu- 
kocyte population 30 min after endotoxin ad- 
0: 15: JO 45 60 75 90 105 I20 135 150 16.5 190 
Time (Minutes) 
FIG. 7. Temperature increased gradually in ah dogs aher 
endotoxin (E), with no significant difference between 
treatment (T) groups. 

























































14.2 f  1.9 t 1.3kO.3 
22.5 f  2.7 t 4.4 f  0.8 



















2.53 f  0.08 
2.5 1 f  0.05 
2.47 k 0.05 
t 2.46 -+ 0.10 
2.48 -+ 0.05 
t 2.3 1 2 0.05 
100+23 
263 + 53 
283 f  59 
* 8364 k 3910 
* 620712644 
* 12332 f  5031 
133*9 
224 f  46 
212 f  36 
t 1497f519 
* 1246f608 




t 26 f  10 
*44*15 
21+9 
7.8 k 0.9 
6.2 + 1.6 
11.9k2.2 
t 15.1 k2.1 
t 12.0 + 2.8 
t 19.7k2.1 
5.5 f  0.3 
8.5 XL 1.7 
13.2f5.1 
t 140+40 
t 103+ 15 
t507+49 
t 1.4kO.3 
t 2.5 f  0.5 









t 53 -+ 12 
t 2.30 f  0.13 
2.29aO.11 










t 16.4 -t 1.3 
t 14.21 1.1 




Note. X + SEM. Within group statistics (paired Student’s t test): * P < 0.10, t P < 0.05, t P < 0.01, comparison of 
baseline vs 30- and 90-min samples. Between group statistics (non-paired Student’s t test): baseline: WBC, N > C,V, 
P < 0.04; hematocrit, V > C, P < 0.03; platelets, C > N,V, P < 0.03; epinephrine, N,V > C, P < 0.03. 30 min: ionized 
calcium, C,N > V, P < 0.05; vasopressin, V > C,N, P < 0.01. 90 min: PMN, V > C, P = 0.06; cortisol, V > C,N, P 
< 0.01; vasopressin, V > C,N, P < 0.01. Abbreviations: C, control, N, naloxone; V, vasopressin antagonist; WBC, 
white blood cells; PMN, polymorphonuclear leukocytes; RBC, red blood cells. 
ministration (Table 2). Lymphocytic and groups had decreased to 39% of baseline, dif- 
mononuclear cells were preserved. Peripheral ferences that were statistically significant and 
platelet count also decreased significantly in that persisted for 90 min. Hematocrit in- 
all treatment groups after endotoxin admin- creased progressively in all dogs during the 
istration. After 30 min, platelet counts in all study, reaching levels of 123% of baseline 
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by 90 min after endotoxin administration 
(Table 2). 
During this study, ionized calcium de- 
creased slightly in all dogs, to 9 1% of baseline 
by 90 min after endotoxin administration. 
This decrease was statistically significant only 
for control and AVP antagonist animals. Dogs 
treated with AVP antagonist showed a more 
rapid decrease in ionized calcium, significantly 
different from control and naloxone animals 
at 30 min (P c 0.05, Table 2). Epinephrine 
and norepinephrine showed considerable 
variance between individual dogs, but both 
catecholamines increased profoundly in all 
treatment groups by 30 min after endotoxin 
administration, being statistically equivalent 
in the three treatment groups (Table 2). 
Total hemolytic complement was activated 
in all treatment groups, as indicated by a de- 
crease in percent lysis of sensitized sheep red 
blood cells at 30 and 90 min after endotoxin 
administration (Table 2). There appeared to 
be more complement activation in control 
animals than in naloxone or AVP antagonist 
treated dogs. At 90 min, available hemolytic 
complement had decreased to 25% of its base- 
line level in control dogs, compared with de- 
creases to only 63 and 59% of baseline in‘nal- 
oxone- and AVP antagonist-treated dogs. Due 
to the large variance among all animals, how- 
ever, these changes were not statistically sig- 
nificant. 
Plasma cortisol increased after endotoxin 
administration in all treatment groups, in- 
creasing 1.8 times baseline by 30 min, and to 
more than twice baseline by 90 min. Although 
AVP antagonist-treated dogs had significantly 
greater cortisol levels by 90 min than both 
naloxone (P < 0.01) and control (P < 0.03) 
dogs, the percentage change compared to 
baseline was comparable in these three groups 
(increases of 210% in control, 230% in nal- 
oxone and 2 12% in AVP antagonist groups). 
Plasma AVP increased markedly after en- 
dotoxin administration. By 30 min, AVP in 
control animals had increased 27 times base- 
line, with a persistent elevation of 11 times 
baseline at 90 min. Dogs treated with naloxone 
showed a 1Cfold increase in AVP by 30 min, 
decreasing to 10 times baseline by 90 min. Al- 
though this 30 min AVP value appeared to be 
less than that seen in control animals, this was 
not statistically significant (Table 2). AVP an- 
tagonist treated dogs showed a much greater 
(6 l-fold) increase in plasma AVP at 30 min 
and a 28-fold increase at 90 min, statistically 
greater than both control and naloxone-treated 
dogs (P < 0.01). Due to the cross-reactivity of 
AVP with the AVP antagonist, however, it is 
estimated that this difference represented the 
amount of antagonist administered. Assuming 
an initial volume of distribution for AVP an- 
tagonist of 67 ml/kg [22], the 10 /*g/kg dose 
of antagonist would have resulted in a mea- 
surable 685 pg/ml AVP activity, based on the 
0.46% cross-reactivity. Assuming that the vol- 
ume of distribution increased and noting the 
antagonist half-life of 3-4 hr [22], the antag- 
onist activity measured 15 and 75 min after 
administration is sufficient to explain the dif- 
ference in AVP activity measured between 
control or naloxone dogs and the AVP antag- 
onist group. 
Although there was no statistically signifi- 
cant difference in survival between treatment 
groups, there was a tendency for improved 
survival among AVP antagonist treated dogs 
(Fig. 8). Mean survival was 1.4 days in control, 
2.2 days in naloxone, and 4.0 days in AVP 
antagonist groups. Median survival of 1,2, and 
FIG. 8. Survival after E. coli endotoxin shock (0.75 mg/ 
kg, LDloo at 48 hr) in dogs treated with naloxone, AVP 
antagonist, or saline (control). 
616 JOURNAL OF SURGICAL RESEARCH: VOL. 41, NO. 6, DECEMBER 1986 
3 days, respectively, for these treatment groups 
also suggested an improved survival after AVP 
antagonist treatment, and intermediate sur- 
vival after naloxone treatment. The only long- 
term survivor among these dogs was in the 
AVP antagonist group, and this animal ap- 
peared healthy when sacrificed at 7 days. Dogs 
treated with AVP antagonist were subjectively 
improved immediately after drug treatment 
when compared with both control and nal- 
oxone dogs. AVP antagonist treated dogs were 
less lethargic and had fewer symptoms of gas- 
trointestinal emptying than did control or 
naloxone-treated animals. 
DISCUSSION 
In this study, E. coli endotoxin administered 
to awake dogs caused a rapid, 25-fold increase 
in plasma AVP levels. Wilson et al. have pre- 
viously reported increased AVP levels in dogs 
and baboons after endotoxin or live E. coli 
shock. In their study, the rapid increase in 
AVP appeared to be stimulated by the effect 
of decreased venous return on left atrial stretch 
receptors, since MAP had not yet decreased 
sufficiently to involve baroreceptors [44]. 
These investigators found peak AVP concen- 
trations 30 min after endotoxin administration 
that were equal to or greater than those found 
in our study. At such high concentrations, 
AVP is known to have cardiac depressant ef- 
fects [ 111. Even modest doses of AVP reduce 
CO and increase TPR in normal, conscious 
dogs [29]. In an isolated canine left ventricle 
preparation, Wilson et al. showed that AVP 
infusion has direct myocardial depressant ef- 
fects, decreasing contractility despite relatively 
normal coronary blood flow [43]. Clinically, 
myocardial dysfunction with reduced cardiac 
output is a side effect of AVP infusion used to 
treat gastrointestinal hemorrhage [38]. 
The above observations promote the hy- 
pothesis that excessively high AVP levels in 
septic or endotoxin shock might actually have 
detrimental cardiovascular effects. In this set- 
ting, AVP is secreted in response to barore- 
ceptor or left atria1 stretch receptor stimuli 
provoked by hypotension or decreased venous 
return. These stimuli increase plasma AVP 
concentration in excess of those normally re- 
quired to achieve osmotic or fluid balance 
during water deprivation [44]. Such observa- 
tions have led to increased recognition of a 
role for AVP in cardiovascular control [29]. 
In fact, AVP blockade in dogs subjected to 
mild hemorrhage results in significantly greater 
hypotension, suggesting that AVP has a sup- 
portive cardiovascular effect during mild 
hemorrhage. Data from our experiment, how- 
ever, suggest that in canine endotoxin shock, 
AVP secretion has gone awry; that is, excessive 
concentrations of AVP resulted in detrimental 
cardiovascular effects. 
The AVP antagonist used in our study has 
been shown to predominantly block pressor 
rather than antidiuretic effects of AVP [22]. It 
is therefore a useful agent to probe the poten- 
tial cardiovascular effects of AVP in shock. To 
our knowledge, this report is the first docu- 
mentation that AVP blockade after endotoxin 
administration significantly improves cardiac 
performance in awake dogs. In fact, AVP an- 
tagonist administered 15 min after endotoxin 
actually normalized CO and MAP by im- 
proving LV dP/dt and increasing HR. Tachy- 
cardia seen after AVP antagonist may repre- 
sent an increased cardiac responsiveness to 
circulating epinephrine, shown to be signifi- 
cantly elevated in these dogs. Archer et al. have 
shown that perfusion of an isolated canine 
heart with endotoxin significantly reduces the 
normal cardiac response to epinephrine [I]. 
Furthermore, Wilson et al. have shown that 
epinephrine can reverse myocardial depression 
caused by AVP in the isolated canine left ven- 
tricle [43]. 
Since the initial reports of Faden and Hol- 
aday, naloxone treatment of endotoxin and 
septic shock has received considerable exper- 
imental and clinical support [7, 8, 311. In our 
study, hemodynamic improvements seen after 
naloxone treatment agree with reports of the 
salutary effects of opiate antagonism in these 
studies [35, 361. Although /3-endorphin was 
not directly measured in our experiment, it 
would predictably have increased, based on 
the measured increases in plasma cortisol, 
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since P-endorphin and ACTH are known to 
be secreted concomitantly from the same pre- 
cursor [ 15, 271. Experimental evidence of a 
close interrelationship between P-endorphin 
and vasopressin secretion has prompted spec- 
ulation that vasopressin, in fact, might mediate 
effects attributed to &endorphin [ 131. In rab- 
bits, both IV and third ventricular injection 
of /3-endorphin stimulated a rapid increase in 
plasma AVP concentration [9,41]. Naloxone 
did not block this increased AVP secretion in 
rabbits, suggesting that a naloxone indepen- 
dent opiate receptor is responsible [9]. In man, 
however, naloxone has been shown to decrease 
plasma AVP concentration and prevent AVP 
increases normally caused by orthostatic hy- 
potension [26]. Thus, data exist to indicate that 
fi-endorphin and naloxone may have different 
effects on AVP secretion in different species 
and after different stimuli [ 14, 20, 2 11. 
Based on the above studies, a complex in- 
teraction appears to exist between AVP and 
&endorphin. Recent experiments suggest that 
endogenous opiates may, in fact, promote 
AVP secretion by inhibiting oxytocin release 
[2, 391. Furthermore, Gillies et al. reported 
that AVP may act as a corticotrophin releasing 
factor in the rat and, therefore, may be capable 
of promoting endorphin secretion [ 121. Based 
on this potential interaction of AVP and fi- 
endorphin, we were stimulated to measure 
cortisol and AVP concentration in both nal- 
oxone- and AVP antagonist-treated dogs. Our 
data indicate that the hemodynamic effects 
seen after naloxone treatment were not me- 
diated by AVP inhibition, since AVP was 
markedly elevated despite naloxone treatment, 
Conversely, increased cortisol in dogs receiving 
AVP antagonist indicates that AVP blockade 
did not achieve its hemodynamic effects by 
reducing /3-endorphin secretion. 
Despite extensive investigation, the under- 
lying mechanisms for cardiac depression and 
hypotension in endotoxin shock are unclear. 
Although AVP appears to have a significant 
role in the current model, its interaction with 
other vasoactive factors is undoubtedly com- 
plex. In an attempt to further characterize our 
model, a variety of other hematologic param- 
eters were measured. As expected, endotoxin 
induced marked leukopenia and thrombocy- 
topenia, associated with complement activa- 
tion. These effects are well documented in this 
and other endotoxin shock models [30], and 
were largely unaffected by the drug treatment 
used in the study. Although not statistically 
significant, there appeared to be less comple- 
ment activation and less depression of poly- 
morphonuclear leukocytes in both naloxone- 
and AVP antagonist-treated dogs. This trend 
suggests that improved cardiovascular perfor- 
mance might reduce complement activation, 
which is otherwise aggravated by reduced cap- 
illary blood flow. 
Reduced ionized calcium in baboon septic 
shock has been reported by Trunkey et al., 
who concluded that calcium reduction con- 
tributes to decreased myocardial contractility 
[40]. Although reduced ionized calcium is as- 
sociated with septic shock, in some cases this 
reduction might indicate a favorable move- 
ment of calcium into cells, essential for the 
action of certain hormones, such as catechol- 
amines [ lo]. The early decrease in serum ion- 
ized calcium seen in AVP antagonist-treated 
dogs in our study was associated with positive 
hemodynamic results, and thus, might reflect 
favorable cellular calcium uptake and utili- 
zation. 
Although there appears to be ample support 
for a direct cardiac mechanism to explain fa- 
vorable cardiovascular effects produced by 
AVP blockade in this study, other explanations 
are possible. In dogs, endotoxin produces 
marked mesenteric vasoconstriction, as op- 
posed to primates, where slight vasodilation 
may occur [4]. In fact, sequelae of mesenteric 
&hernia are a prominant cause of mortality 
in the canine model. Despite improved early 
survival of dogs in endotoxin shock after nal- 
oxone treatment, significant mesenteric isch- 
emia persists, prompting Reynolds et al. to 
suggest that severe intestinal ischemic damage 
might abrogate the early beneficial effects of 
naloxone [ 361. High plasma AVP levels found 
in our study suggest a potential role for AVP 
in promoting mesenteric vasoconstriction. 
Relief of this vasoconstriction by AVP block- 
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ade has the potential to reduce this contribu- 
tion to mortality in canine endotoxin shock. 
Furthermore, myocardial depressant factors, 
suggested by Lefer et al. to originate in isch- 
emit intestine during shock [25], might be re- 
duced. If this mechanism proves to be impor- 
tant for the favorable effects of AVP blockade 
in canine endotoxin shock, considerable cau- 
tion should be exercised in generalizing these 
results to primates, where significant splanch- 
nit vasoconstriction does not occur during 
endotoxin shock. 
It would appear teleologically unsound for 
elevated AVP in endotoxin shock to precipi- 
tate myocardial depression. Early cardiovas- 
cular collapse during endotoxin shock in rats 
and dogs, however, is primarily due to hepatic 
venous pooling that probably stimulates early 
AVP release [19, 42, 441. As hepatic venous 
congestion resolves, this initially favorable 
AVP response might become excessive. It is 
known that AVP depresses renin secretion, an 
alternative pressor mechanism with more 
beneficial cardiac effects [28]. AVP also re- 
duces cardiac sensitivity to epinephrine [43]. 
Thus, although AVP may be beneficial in ca- 
nine or rat endotoxin shock during early 
splanchnic venous pooling, continuation of 
this response could be detrimental. If this hy- 
pothesis is correct, we would predict that AVP 
blockade prior to endotoxin administration 
would have detrimental effects in rats or dogs. 
In fact, Brattleboro rats that congenitally lack 
AVP demonstrate significantly worse hypo- 
tension after endotoxin administration than 
Sprague-Dawley rats with AVP present [3]. 
Additional experiments are required to clarify 
this hypothesis. 
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